Scilex Holding Company
Prices are adjusted according to historical splits.
Vitals
- Today's Low:
- $0.35
- Today's High:
- $0.4799
- Open Price:
- $0.4798
- 52W Low:
- $0.1003
- 52W High:
- $4.5
- Prev. Close:
- $0.3838
- Volume:
- 21143
Company Statistics
- Market Cap.:
- $0
- Book Value:
- -1.161
- Revenue TTM:
- $34.38 million
- Operating Margin TTM:
- -120.16%
- Gross Profit TTM:
- $0
- Profit Margin:
- -138.01%
- Return on Assets TTM:
- 0%
- Return on Equity TTM:
- 0%
Company Profile
Scilex Holding Company had its IPO on 2021-03-08 under the ticker symbol SCLXW.
The company operates in the Healthcare sector and Drug Manufacturers-General industry. Scilex Holding Company has a staff strength of 76 employees.
Stock update
Shares of Scilex Holding Company opened at $0.48 at the start of the last trading session i.e. 2023-09-12.
The stocks traded within a range of $0.35 - $0.48, and closed at $0.43.
This is a +12.04% increase from the previous day's closing price.
A total volume of 21,143 shares were traded at the close of the day’s session.
In the last one week, shares of Scilex Holding Company have slipped by -28.32%.
Scilex Holding Company's Key Ratios
Scilex Holding Company has a market cap of $0, indicating a price to book ratio of 0 and a price to sales ratio of 0.
In the last 12-months Scilex Holding Company’s revenue was $34.38 million with a gross profit of $0 and an EBITDA of $-37437000. The EBITDA ratio measures Scilex Holding Company's overall financial performance and is widely used to measure its profitability.
In the trailing 12-month period, Scilex Holding Company’s operating margin was -120.16% while its return on assets stood at 0% with a return of equity of 0%.
In Q2, Scilex Holding Company’s quarterly earnings growth was a positive 0% while revenue growth was a positive 36.7%.
Scilex Holding Company’s PE and PEG Ratio
- Forward PE
- 0
- Trailing PE
- 0
- PEG
Its diluted EPS in the last 12-months stands at $0 per share while it has a forward price to earnings multiple of 0 and a PEG multiple of . A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.
The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into Scilex Holding Company’s profitability.
Scilex Holding Company stock is trading at a EV to sales ratio of 0 and a EV to EBITDA ratio of 0. Its price to sales ratio in the trailing 12-months stood at 0.
Scilex Holding Company stock pays annual dividends of $0 per share, indicating a yield of 0% and a payout ratio of 0%.
Balance sheet and cash flow metrics
- Total Assets
- $126.46 million
- Total Liabilities
- $103.58 million
- Operating Cash Flow
- $0
- Capital Expenditure
- $0
- Dividend Payout Ratio
- 0%
Scilex Holding Company ended 2024 with $126.46 million in total assets and $0 in total liabilities. Its intangible assets were valued at $126.46 million while shareholder equity stood at $10.42 million.
Scilex Holding Company ended 2024 with $0 in deferred long-term liabilities, $103.58 million in other current liabilities, 15000.00 in common stock, $-433316000.00 in retained earnings and $13.48 million in goodwill. Its cash balance stood at $34.12 million and cash and short-term investments were $34.12 million. The company’s total short-term debt was $35,132,000 while long-term debt stood at $0.
Scilex Holding Company’s total current assets stands at $69.25 million while long-term investments were $0 and short-term investments were $0. Its net receivables were $27.57 million compared to accounts payable of $11.41 million and inventory worth $3.11 million.
In 2024, Scilex Holding Company's operating cash flow was $0 while its capital expenditure stood at $0.
Comparatively, Scilex Holding Company paid $0 in dividends in 2024.
Other key metrics
- Current Trading Price
- $0.43
- 52-Week High
- $4.5
- 52-Week Low
- $0.1003
- Analyst Target Price
- $
Scilex Holding Company stock is currently trading at $0.43 per share. It touched a 52-week high of $4.5 and a 52-week low of $4.5. Analysts tracking the stock have a 12-month average target price of $.
Its 50-day moving average was $1.08 and 200-day moving average was $1.25 The short ratio stood at 0 indicating a short percent outstanding of 0%.
Around 0% of the company’s stock are held by insiders while 0% are held by institutions.
Frequently Asked Questions About Scilex Holding Company
Similar Industry Stocks (Drug Manufacturers-General)
Most Active
Top Gainers
Top Losers
About
Scilex Holding Company, a biopharmaceutical company, focuses on developing and commercializing non-opioid therapies for patients with acute and chronic pain. The company’s principal product includes ZTlido 1.8%, a prescription lidocaine topical product for the relief of neuropathic pain related with post-herpetic neuralgia, which is a form of post-shingles nerve pain. It also offers SP-102 or SEMDEXA, a viscous gel formulation of corticosteroid for epidural injections that is in a Phase 3 clinical trial to treat lumbosacral radicular pain; SP-103 for the treatment of low back pain, which is in Phase 2 clinical trails; and SP-104, a novel low-dose delayed-release naltrexone hydrochloride formulation for the treatment of fibromyalgia that is in Phase 1 clinical trials. The company is headquartered in Palo Alto, California. Scilex Holding Company is a subsidiary of Sorrento Therapeutics, Inc.